Zaloguj się

Gotowe bibliografie tematyczne / Cervical Cancer / Artykuły w czasopismach

Artykuły w czasopismach na temat „Cervical Cancer”

Kliknij ten link, aby zobaczyć inne rodzaje publikacji na ten temat: Cervical Cancer.

Autor: Grafiati

Data publikacji: 4 czerwca 2021

Data aktualizacji: 6 września 2023

Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych

Wybierz rodzaj źródła:

Sprawdź 50 najlepszych artykułów w czasopismach naukowych na temat „Cervical Cancer”.

Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.

Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.

Przeglądaj artykuły w czasopismach z różnych dziedzin i twórz odpowiednie bibliografie.

1

S Kadam, Sachin, i Tejaswini Kadam. "Endometrial Cancer with Cervical Extension Masquerading as Cervical Cancer". Cancer Research and Cellular Therapeutics 6, nr 3 (16.05.2022): 01–03. http://dx.doi.org/10.31579/2640-1053/118.

Pełny tekst źródła

Streszczenie:

The incidence and prevalence of endometrial cancer is less as compared to cervical cancer. Worldwide, in 2018, near about 382000 new cases of endometrial cancer were diagnosed and around 90000 women were died from the disease

Style APA, Harvard, Vancouver, ISO itp.

2

Yang, Nan, Esther R. Nijhuis, Haukeline H. Volders, Jasper J. H. Eijsink, Ágnes Lendvai, Bo Zhang, Harry Hollema, Ed Schuuring, G. Bea A. Wisman i Ate G. J. van der Zeea. "Gene Promoter Methylation Patterns throughout the Process of Cervical Carcinogenesis". Analytical Cellular Pathology 32, nr 1-2 (1.01.2010): 131–43. http://dx.doi.org/10.1155/2010/306087.

Pełny tekst źródła

Streszczenie:

Objectives: To determine methylation status of nine genes, previously described to be frequently methylated in cervical cancer, in squamous intraepithelial lesions (SIL).Methods: QMSP was performed in normal cervix, low-grade (L)SIL, high-grade (H)SIL, adenocarcinomas and squamous cell cervical cancers, and in corresponding cervical scrapings.Results: Only CCNA1 was never methylated in normal cervices and rarely in LSILs. All other genes showed methylation in normal cervices, with CALCA, SPARC and RAR-β2 at high levels. Methylation frequency of 6 genes (DAPK, APC, TFPI2, SPARC, CCNA1 and CADM1) increased with severity of the underlying cervical lesion. DAPK showed the highest increase in methylation frequency between LSIL and HSIL (10% vs. 40%, p < 0.05), while CCNA1 and TFPI2 were most prominently methylated in cervical cancers compared to HSILs (25% vs. 52%, p < 0.05, 30% vs. 58%, p < 0.05). CADM1 methylation in cervical cancers was related to depth of invasion (p < 0.05) and lymph vascular space involvement (p < 0.01), suggesting a role in invasive potential of cervical cancers. Methylation ratios in scrapings reflected methylation status of the underlying lesions (p < 0.05).Conclusion: Methylation of previously reported cervical cancer specific genes frequently occurs in normal epithelium. However, frequency of methylation increases during cervical carcinogenesis, with CCNA1 and DAPK as the best markers to distinguish normal/LSIL from HSIL/cancer lesions.

Style APA, Harvard, Vancouver, ISO itp.

3

Isakova, Dilnoza, Zebiniso Inakova, Ranokhon Solieva, Matkarimov Bakhtiyorjon, Yorkinoy Farmankulova i Dilfuzahon Mamarasulova. "Clinical Echocolpocsopy Features Of Cervical Cancer". American Journal of Medical Sciences and Pharmaceutical Research 02, nr 07 (31.07.2020): 123–29. http://dx.doi.org/10.37547/tajmspr/volume02issue07-16.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

4

Singh Randhawa, Amritjot. "Metastatic Breast Cancer to the Uterine Cervix Mimicking Cervical Cancer". Indian Journal of Cancer Education and Research 8, nr 1 (1.06.2020): 49–52. http://dx.doi.org/10.21088/ijcer.2321.9815.8120.8.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

5

AziziKia, Hani, Hamidreza Didar, Azin Teymourzadeh, Amin Nakhostin-Ansari, Pooya Jafari Doudaran, Bahareh Ferasatifar, Armin Hoveidaei i Gholamreza Roshandel. "Uterine and Cervical Cancer in Iran: An epidemiologic analysis of the Iranian National Population-Based Cancer Registry". Archives of Iranian Medicine 26, nr 1 (1.01.2023): 1–7. http://dx.doi.org/10.34172/aim.2023.01.

Pełny tekst źródła

Streszczenie:

Background: Gynecologic cancers, including neoplasms of the cervix and uterine, are the fourth most common malignancies, causing 3.46% of deaths in women aged 15 to 59. Objectives: We aimed to report the Iranian National Population-based Cancer Registry (INPCR) results for Cervical and Uterine cancers in 2017. Methods: The total population of Iran in 2017 was 80881792. INPCR collected data on cervical and uterine cancer incidence from 31 provinces of Iran. In this project, we retrospectively examined all the country’s regions in terms of screening for the existence of these two cancers. The registry data bank in Iran was used. Results: Overall, 3481 new cervical and uterine cancer cases were registered in INPCR, including 842 cases of cervical cancer (with a crude rate of 1.04) and 2639 cases of uterine cancer (with a crude rate of 3.26). The average age-standardized incidence rate (ASR) was 0.99 for cervical cancer and 3.29 for uterine cancer. Out of 3481 new cervical and uterine cancer cases, 2887 were registered with pathological findings and 594 without pathological confirmation. In cervical cancers, the highest rate was related to squamous cell carcinoma, with 486 cases (57.72%). Conclusion: Our results showed that Iran is a low-risk area for the incidence of cervical and uterine cancers. In this study, the highest rate of cervical cancer was related to squamous cell carcinoma, confirming previous reports. However, this rate was lower than previous studies and suggested an increase in other types of cervical cancer in Iran.

Style APA, Harvard, Vancouver, ISO itp.

6

H.K, Dr Sharath Kumar. "Immuno-Histochemical Study of P16INK4A in Cervical Intraepithelial Neoplasia and Cervical Cancer". Journal of Medical Science And clinical Research 05, nr 01 (8.01.2017): 15415–22. http://dx.doi.org/10.18535/jmscr/v5i1.37.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

7

Der, EM, K. Adu-Bonsaffoh, Y. Tettey, RA Kwame-Aryee, JD Seffah, H. Alidu i RK Gyasi. "Clinico-pathological characteristics of cervical cancer in Ghanaian women". Journal of Medical and Biomedical Sciences 3, nr 3 (13.01.2015): 27–32. http://dx.doi.org/10.4314/jmbs.v3i3.5.

Pełny tekst źródła

Streszczenie:

Cervical cancer is a major cause of cancer related mortality in the developing countries, although preventable. The aim of this study was to use a retrospective descriptive study to determine the prevalence and the clinico-pathological characteristics of cervical cancer among genital tract ma-lignancies. This study reviewed all histologically confirmed female genital tract malignancies for cervical cancers from January 2002 to December 2011. The clinico-pathological features of women with cervical cancer were analyzed using SPSS software (version 18). A total of 1011(70.8%) out of 1,427 female genital tract malignancies were cervical cancers. The average prevalence of cervical cancer was 71.0%. The mean age of women with cervical cancer was 57.8(SD=13.8) years. The youngest patient was 22 years. The commonest (76.9%) presentation was bleeding per vaginalm followed by fungating cervical masses (12.4%). Majority (88.9%) of the bleeding were unprovoked and in postmenopausal women (98.8%). The major types of cervical cancers were Squamous cell carcinoma (SCC) (90.1%) and adenocarcinoma (5.8%), both were common in the elderly. The com-mon histological subtypes of cervical cancers in the study were; keratinizing SCC (73.3%), non-keratinizing SCC (14.7%), endometroid adenocarcinoma (4.5%), adenosquamous carcinoma (2.6%) and basaloid SCC (1.4%). This study found high prevalence of cervical cancer among female geni-tal tract cancers in Accra Ghana. The women were relatively older and presented with advanced stage of the disease. SCC was the major histological type of cervical cancer.Keywords: Ghana, cervical cancer, postmenopausal, women, premalignant, genital tract

Style APA, Harvard, Vancouver, ISO itp.

8

Iram, Ayesha. "Cancer Screening Technology and Attitude of Women Towards Cervical Cancer". TEXILA INTERNATIONAL JOURNAL OF ACADEMIC RESEARCH 9, nr 3 (30.07.2022): 145–67. http://dx.doi.org/10.21522/tijar.2014.09.03.art013.

Pełny tekst źródła

Streszczenie:

Cervical cancer claims over a quarter of a million lives of women annually worldwide. It is believed to be the second most common cancer among women worldwide. Screening is used to detect precancerous changes or early cancers before signs or symptoms of cancer occur. The first case of cervical cancer was founded in the 1970s by Harald Zur Hausen. It is believed to be the second most common cancer among women worldwide. Females becoming sexually active in early age with multiple partners are on high risk. Virtually all cervical cancers are associated with human papilloma viruses (HPV). This study was conducted to understand the levels of knowledge and attitudes of women towards cervical cancer screening in Al Khan Dubai.It assessed the knowledge and attitudes of women about cervical cancer prevention. 70% of the sexually active women really need to go for cancer screening. It shows that 66% of women in al khan are being affected due to lifestyle and it is affecting women’s decision in relation to cervical cancer screening. To improve cervical cancer screening in al khan area, women should be given more information, motivation, awareness, and sensitization, in order to encourage them to go for a cervical cancer screening. Keywords: Cervix, High risk, HPV, Pre-screening methods, Women.

Style APA, Harvard, Vancouver, ISO itp.

9

Dayanand Katke, Rajshree, i Deepti Prasad. "Cervical Cancer Prevention: Current Scenario". Acta Scientific Cancer Biology 4, nr 2 (18.01.2020): 01–03. http://dx.doi.org/10.31080/ascb.2020.04.cervical-cancer-prevention-current-scenario.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

10

Boisen, Michelle, i Richard Guido. "Emerging Treatment Options for Cervical Dysplasia and Early Cervical Cancer". Clinical Obstetrics & Gynecology 66, nr 3 (25.07.2023): 500–515. http://dx.doi.org/10.1097/grf.0000000000000790.

Pełny tekst źródła

Streszczenie:

Discussion of treatment strategies for cervical cancer precursors, review of medical therapies and emerging therapeutics for treatment of cervical cancers, and updates on new approaches to treating early-stage cervical cancers.

Style APA, Harvard, Vancouver, ISO itp.

11

Victor Manuel, Vargas Hernandez. "Toward A Better Screening for Cervical Cancer". Cytology & Histology International Journal 4, nr 1 (2020): 1–6. http://dx.doi.org/10.23880/chij-16000116.

Pełny tekst źródła

Streszczenie:

As cervical cancer screening changes from cytology or Pap test to high-risk human papillomavirus (HPV-ar) test, primary worldwide, effective classification tests to decide who of the positive HPV-ar women should receive additional diagnostic evaluation to avoid unnecessary colposcopies and biopsies; with the evaluation of the performance of the dual staining p16 / Ki-67; and partial genotyping, HPV-16/18 for the triage of women with HPV-ar, positive; for the detection of cervical intraepithelial neoplasia grade 3 or more severe (CIN-3 +) and CIN grade 2 or more severe (CIN-2+), diagnosed within 3 years after taking the sample; better risk stratification for CIN-3+ was demonstrated, compared to Pap; in women with positive results they have a higher risk than with Pap, for CIN-3 + (12.0 vs. 10.3%; 11.6%; P = .005); even with better risk stratification for CIN-3+, compared with Pap in women with HPV-ar, positive, regardless of genotype. The greatest balance against CIN-3+ was observed in HPV-16/18 negative women or with dual negative staining, with a low risk to extend the screening intervals. Double staining triage strategies required substantially fewer colposcopies for the detection of CIC-3+ compared to Pap, with a 32.1% reduction in colposcopies compared to the triage strategy currently recommended in the detection of HPV-ar, with the Pap. The results for CIN-2+ are similar. Conclusions; the management of women with HPV-ar test, positive in the detection of cervical cancer; with support from the Pap and dual staining p16 / Ki-67, alone or in combination with HPV- 16/18 genotyping, it provides better risk stratification than strategies based only on the Pap and in countries such as Mexico, where there is organized infrastructure can detect and prevent the cervical cancer.

Style APA, Harvard, Vancouver, ISO itp.

12

Sharipova, I. P., i E. I. Musabaev. "HUMAN PAPILLOMAVIRUS INFECTION AND CERVICAL CANCER (OWERWIEW)". UZBEK MEDICAL JOURNAL 2, nr 4 (30.04.2021): 23–29. http://dx.doi.org/10.26739/2181-0664-2021-4-4.

Pełny tekst źródła

Streszczenie:

Viral infections are responsible for 15–20% of all human cancers. Infection with oncogenic viruses can contribute to various stages of carcinogenesis. Despite effective screening methods, cervical cancer continues to be a major public health problem. There are large differences in morbidity and mortality from cervical cancer by geographic region. The age-specific prevalence of HPV varies widely in different populations and has shown two peaks of HPV positiveness in young and older women. Around the world, there have been many studies on the epidemiology of HPV infection and oncogenic properties due to different HPV genotypes. However, there are still many countries where population prevalence has not yet been determined. Moreover, screening strategies for cervical cancer differ from country to country. Organized cervical screening programs are potentially more effectivethan opportunistic screening programs.Key words:Human papillomavirus, cervical cancer, screening, dysplasia

Style APA, Harvard, Vancouver, ISO itp.

13

Subbamma, B. Venkata, i Dr D. Sai Sujatha Dr. D. Sai Sujatha. "Knowledge on Cervical Cancer Among Urban Women". International Journal of Scientific Research 2, nr 9 (1.06.2012): 17–18. http://dx.doi.org/10.15373/22778179/sep2013/155.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

14

BE, R. Aruna Sankari. "Cervical Cancer Detection Using Support Vector Machine". International journal of Emerging Trends in Science and Technology 04, nr 03 (31.03.2017): 5033–38. http://dx.doi.org/10.18535/ijetst/v4i3.08.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

15

Ansink, A. C., R. Tolhurst, R. Haque, S. Saha, S. Datta i N. R. van den Broek. "Cervical cancer in Bangladesh: community perceptions of cervical cancer and cervical cancer screening". Transactions of the Royal Society of Tropical Medicine and Hygiene 102, nr 5 (maj 2008): 499–505. http://dx.doi.org/10.1016/j.trstmh.2008.01.022.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

16

Perkins, Rebecca B., Nicolas Wentzensen, Richard S. Guido i Mark Schiffman. "Cervical Cancer Screening". JAMA 330, nr 6 (8.08.2023): 547. http://dx.doi.org/10.1001/jama.2023.13174.

Pełny tekst źródła

Streszczenie:

ImportanceEach year in the US, approximately 100 000 people are treated for cervical precancer, 14 000 people are diagnosed with cervical cancer, and 4000 die of cervical cancer.ObservationsEssentially all cervical cancers worldwide are caused by persistent infections with one of 13 carcinogenic human papillomavirus (HPV) genotypes: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68. HPV vaccination at ages 9 through 12 years will likely prevent more than 90% of cervical precancers and cancers. In people with a cervix aged 21 through 65 years, cervical cancer is prevented by screening for and treating cervical precancer, defined as high-grade squamous intraepithelial lesions of the cervix. High-grade lesions can progress to cervical cancer if not treated. Cervicovaginal HPV testing is 90% sensitive for detecting precancer. In the general population, the risk of precancer is less than 0.15% over 5 years following a negative HPV test result. Among people with a positive HPV test result, a combination of HPV genotyping and cervical cytology (Papanicolaou testing) can identify the risk of precancer. For people with current precancer risks of less than 4%, repeat HPV testing is recommended in 1, 3, or 5 years depending on 5-year precancer risk. For people with current precancer risks of 4% through 24%, such as those with low-grade cytology test results (atypical squamous cells of undetermined significance [ASC-US] or low-grade squamous intraepithelial lesion [LSIL]) and a positive HPV test of unknown duration, colposcopy is recommended. For patients with precancer risks of less than 25% (eg, cervical intraepithelial neoplasia grade 1 [CIN1] or histologic LSIL), treatment-related adverse effects, including possible association with preterm labor, can be reduced by repeating colposcopy to monitor for precancer and avoiding excisional treatment. For patients with current precancer risks of 25% through 59% (eg, high-grade cytology results of ASC cannot exclude high-grade lesion [ASC-H] or high-grade squamous intraepithelial lesion [HSIL] with positive HPV test results), management consists of colposcopy with biopsy or excisional treatment. For those with current precancer risks of 60% or more, such as patients with HPV-16–positive HSIL, proceeding directly to excisional treatment is preferred, but performing a colposcopy first to confirm the need for excisional treatment is acceptable. Clinical decision support tools can facilitate correct management.Conclusions and RelevanceApproximately 100 000 people are treated for cervical precancer each year in the US to prevent cervical cancer. People with a cervix should be screened with HPV testing, and if HPV-positive, genotyping and cytology testing should be performed to assess the risk of cervical precancer and determine the need for colposcopy or treatment. HPV vaccination in adolescence will likely prevent more than 90% of cervical precancers and cancers.

Style APA, Harvard, Vancouver, ISO itp.

17

Ma, Zhifang, Jie Chen, Ting Luan, Chengzhuo Chu, Wangfei Wu, Yichao Zhu i Yun Gu. "Proteomic analysis of human cervical adenocarcinoma mucus to identify potential protein biomarkers". PeerJ 8 (28.07.2020): e9527. http://dx.doi.org/10.7717/peerj.9527.

Pełny tekst źródła

Streszczenie:

Background Cervical cancer is the most common gynecological cancer, encompassing cervical squamous cell carcinoma, adenocarcinoma, and other epithelial tumors. There are many diagnostic methods to detect cervical cancers but no precision screening tool for cervical adenocarcinoma at present. Material and methods The cervical mucus from three normal cervices (Ctrl), three endocervical adenocarcinoma (EA), and three cervical adenocarcinoma in situ (AIS) was collected for proteomic analysis. The proteins were screened using liquid chromatography-mass spectrometry analysis (LC-MS). The biological function of the differently expressed proteins were predicted by Gene Ontology (GO). Results A total of 711 proteins were identified, including 237 differently expressed proteins identified in EA/Ctrl comparison, 256 differently expressed proteins identified in AIS/Ctrl comparison, and 242 differently expressed proteins identified in AIS/EA comparison (up-regulate ≥ 1.5 or down-regulate ≤ 0.67). Functional annotation was performed using GO analysis on 1,056 differently expressed proteins to identify those that may impact cervical cancer, such as heme protein myeloperoxidase, which is involved in the immune process, and APOA1, which is associated with lipid metabolism. Conclusion We used proteomic analysis to screen out differently expressed proteins from normal cervical mucus and cervical adenocarcinoma mucus samples. These differently expressed proteins may be potential biomarkers for the diagnosis and treatment of cervical adenocarcinoma but require additional study.

Style APA, Harvard, Vancouver, ISO itp.

18

Berry, Lisa. "Cervical cancer". Cancer Nursing Practice 15, nr 10 (12.12.2016): 11. http://dx.doi.org/10.7748/cnp.15.10.11.s10.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

19

Greer, Benjamin E., Wui-Jin Koh, Nadeem R. Abu-Rustum, Sachin M. Apte, Susana M. Campos, John Chan, Kathleen R. Cho i in. "Cervical Cancer". Journal of the National Comprehensive Cancer Network 8, nr 12 (grudzień 2010): 1388–416. http://dx.doi.org/10.6004/jnccn.2010.0104.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

20

Koh, Wui-Jin, Benjamin E. Greer, Nadeem R. Abu-Rustum, Sachin M. Apte, Susana M. Campos, John Chan, Kathleen R. Cho i in. "Cervical Cancer". Journal of the National Comprehensive Cancer Network 11, nr 3 (marzec 2013): 320–43. http://dx.doi.org/10.6004/jnccn.2013.0043.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

21

McKay, Lindsay. "Cervical cancer". Nursing Standard 23, nr 46 (22.07.2009): 59. http://dx.doi.org/10.7748/ns2009.07.23.46.59.c7172.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

22

Goodwin, Peter M. "Cervical Cancer". Oncology Times 44, nr 2 (20.01.2022): 18. http://dx.doi.org/10.1097/01.cot.0000818680.74642.b6.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

23

McKay, Lindsay. "Cervical cancer". Nursing Standard 23, nr 46 (22.07.2009): 59–60. http://dx.doi.org/10.7748/ns.23.46.59.s52.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

24

Hanson, Julie. "Cervical cancer". Nursing Standard 24, nr 13 (2.12.2009): 59–60. http://dx.doi.org/10.7748/ns.24.13.59.s53.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

25

Schneider, Achim, i Lutz Gissmann. "Cervical Cancer". American Journal of Cancer 2, nr 4 (2003): 253–68. http://dx.doi.org/10.2165/00024669-200302040-00004.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

26

Carlson, Robert H. "Cervical Cancer". Oncology Times 36, nr 2 (styczeń 2014): 44–45. http://dx.doi.org/10.1097/01.cot.0000443164.07554.4e.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

27

Carlson, Robert H. "Cervical Cancer". Oncology Times 37, nr 23 (grudzień 2015): 35. http://dx.doi.org/10.1097/01.cot.0000475709.42579.f7.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

28

van NAGELL, JOHN R., LINORE M. DUDIK, ARTHUR L. FRANK, J. PAUL LEIGH, JOSEPH ENGELBERG i DAVID T. ALLEN. "Cervical Cancer". Southern Medical Journal 80, nr 1 (styczeń 1987): 75–81. http://dx.doi.org/10.1097/00007611-198701000-00017.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

29

JONES, HOWARD W. "CERVICAL CANCER". Clinical Obstetrics and Gynecology 33, nr 4 (grudzień 1990): 815. http://dx.doi.org/10.1097/00003081-199012000-00016.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

30

&NA;. "Cervical Cancer". Clinical Obstetrics and Gynecology 33, nr 4 (grudzień 1990): 917–18. http://dx.doi.org/10.1097/00003081-199012000-00028.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

31

D'Addario, Johanna. "Cervical cancer". Journal of the American Academy of Physician Assistants 33, nr 12 (grudzień 2020): 51–52. http://dx.doi.org/10.1097/01.jaa.0000721700.59332.90.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

32

Moore, David H. "Cervical Cancer". Obstetrics & Gynecology 107, nr 5 (maj 2006): 1152–61. http://dx.doi.org/10.1097/01.aog.0000215986.48590.79.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

33

Clark, Max A., William Naahas, Ronald J. Markert i Melvin G. Dodson. "Cervical Cancer". American Journal of Clinical Oncology 14, nr 4 (sierpień 1991): 352–56. http://dx.doi.org/10.1097/00000421-199108000-00016.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

34

Berry, Lisa. "Cervical cancer". Nursing Standard 31, nr 21 (18.01.2017): 15. http://dx.doi.org/10.7748/ns.31.21.15.s17.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

35

Sindos, Michael, Narendra Pisal, Theresa Freeman-Wang i Albert Singer. "Cervical Cancer". Obstetrics & Gynecology 101, nr 6 (czerwiec 2003): 1354–55. http://dx.doi.org/10.1097/00006250-200306000-00045.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

36

Davy, Margaret. "Cervical Cancer". Obstetrics & Gynecology 101, nr 6 (czerwiec 2003): 1355. http://dx.doi.org/10.1097/00006250-200306000-00046.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

37

Tinari, Mary Alice. "Cervical cancer". Nursing Made Incredibly Easy! 6, nr 6 (listopad 2008): 32–41. http://dx.doi.org/10.1097/01.nme.0000341174.90616.56.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

38

&NA;. "Cervical cancer". Nursing Made Incredibly Easy! 6, nr 6 (listopad 2008): 41–42. http://dx.doi.org/10.1097/01.nme.0000341175.90616.1f.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

39

Lea, Jayanthi S., i Ken Y. Lin. "Cervical Cancer". Obstetrics and Gynecology Clinics of North America 39, nr 2 (czerwiec 2012): 233–53. http://dx.doi.org/10.1016/j.ogc.2012.02.008.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

40

Orr, James W. "Cervical Cancer". Surgical Oncology Clinics of North America 7, nr 2 (kwiecień 1998): 299–316. http://dx.doi.org/10.1016/s1055-3207(18)30272-2.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

41

Waggoner, Steven E. "Cervical cancer". Lancet 361, nr 9376 (czerwiec 2003): 2217–25. http://dx.doi.org/10.1016/s0140-6736(03)13778-6.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

42

Waugh, M. A. "CERVICAL CANCER". Lancet 328, nr 8517 (listopad 1986): 1226. http://dx.doi.org/10.1016/s0140-6736(86)92243-9.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

43

Cohen, Paul A., Anjua Jhingran, Ana Oaknin i Lynette Denny. "Cervical cancer". Lancet 393, nr 10167 (styczeń 2019): 169–82. http://dx.doi.org/10.1016/s0140-6736(18)32470-x.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

44

Berek, Jonathan S. "Cervical Cancer". Cancer Journal 9, nr 5 (wrzesień 2003): 325–26. http://dx.doi.org/10.1097/00130404-200309000-00001.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

45

Wuerthner, Barbara A., i Maria Avila-Wallace. "Cervical cancer". Nurse Practitioner 41, nr 9 (wrzesień 2016): 18–23. http://dx.doi.org/10.1097/01.npr.0000490390.43604.5f.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

46

Small, William, Monica A. Bacon, Amishi Bajaj, Linus T. Chuang, Brandon J. Fisher, Matthew M. Harkenrider, Anuja Jhingran i in. "Cervical Cancer". Obstetrical & Gynecological Survey 72, nr 11 (listopad 2017): 654–55. http://dx.doi.org/10.1097/01.ogx.0000526010.06041.5e.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

47

van Diest, P. J., i H. Holzel. "Cervical cancer". Journal of Clinical Pathology 55, nr 4 (1.04.2002): 241–42. http://dx.doi.org/10.1136/jcp.55.4.241.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

48

Peate, Ian. "Cervical cancer". British Journal of Healthcare Assistants 13, nr 3 (2.03.2019): 110–16. http://dx.doi.org/10.12968/bjha.2019.13.3.110.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

49

Shepherd, John H. "Cervical cancer". Best Practice & Research Clinical Obstetrics & Gynaecology 26, nr 3 (czerwiec 2012): 293–309. http://dx.doi.org/10.1016/j.bpobgyn.2011.12.004.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

50

Stephenson, J. "Cervical Cancer". JAMA: The Journal of the American Medical Association 281, nr 11 (17.03.1999): 978—c—978. http://dx.doi.org/10.1001/jama.281.11.978-c.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

Oferujemy zniżki na wszystkie plany premium dla autorów, których prace zostały uwzględnione w tematycznych zestawieniach literatury. Skontaktuj się z nami, aby uzyskać unikalny kod promocyjny!